Bullish & Foolish
Full TPST fundamentals All 466 on the Survival Watch

TPSTTempest Therapeutics, Inc.

Is Tempest Therapeutics struggling financially?

Yes, by its own account. Tempest Therapeutics told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

14/100

Critical

Sector
Biotech/Pharma
Market cap
$16.6M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 0months

    If the burn speeds up

    Empty by Jun 2026

  • 1month

    If it eases off

    Empty by Jul 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$779K

÷

Cash burned over the last 12 months

$26.8M

What Tempest Therapeutics told the SEC

…expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued. Accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these consolidated financial statements. The accompanying financial statements were prepared on a going concern basis, which…

Tempest Therapeutics, Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 261.5% share-count increase The company issued stock. Each share now owns 72.3% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Debt is large against the cash on hand while the business generates little to service it, which puts lenders ahead of shareholders in the queue.
  • Cash burn is narrowing It is spending 54% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt